Kathleen I Pritchard

Summary

Affiliation: Sunnybrook Health Sciences Centre
Country: Canada

Publications

  1. ncbi Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada Electronic address
    Clin Breast Cancer 13:421-432.e8. 2013
  2. doi Endocrine therapy: is the first generation of targeted drugs the last?
    K I Pritchard
    Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, ON, Canada
    J Intern Med 274:144-52. 2013
  3. doi Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study
    Kathleen I Pritchard
    Ontario Clinical Oncology Group, McMaster University, Hamilton, Canada
    J Clin Oncol 30:1274-9. 2012
  4. ncbi HER2 and responsiveness of breast cancer to adjuvant chemotherapy
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre and the University of Toronto, Toronto, ON, Canada
    N Engl J Med 354:2103-11. 2006
  5. ncbi Combining endocrine agents with chemotherapy: which patients and what sequence?
    Kathleen I Pritchard
    Clinical Trials and Epidemiology, University of Toronto at Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
    Cancer 112:718-22. 2008
  6. doi Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and University of Toronto, 2075 Bayview Avenue, M4N 3M5, Toronto, ON, Canada
    Breast Cancer Res Treat 123:453-61. 2010
  7. doi HER-2 and topoisomerase II as predictors of response to chemotherapy
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre, Department of Medicine, University of Toronto, 2075 Bayview Ave, Toronto, ON, Canada
    J Clin Oncol 26:736-44. 2008
  8. ncbi Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre, Toronto, Canada
    Oncology (Williston Park) 23:27-33. 2009
  9. ncbi Cardiovascular health and aromatase inhibitors
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre, Sunnybrook Health Sciences Centre, and the University of Toronto, Toronto, Ontario, Canada
    Drugs 66:1727-40. 2006
  10. ncbi Risk of chemotherapy induced menopause: more detailed data will lead to improved quality of life
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre, Sunnybrook Health Sciences Centre and the University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Eur J Cancer 43:1644-5. 2007

Detail Information

Publications90

  1. ncbi Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada Electronic address
    Clin Breast Cancer 13:421-432.e8. 2013
    ..Because many women with HR(+) advanced breast cancer are elderly, the tolerability profile of EVE plus EXE in this population is of interest...
  2. doi Endocrine therapy: is the first generation of targeted drugs the last?
    K I Pritchard
    Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, ON, Canada
    J Intern Med 274:144-52. 2013
    ..To date, however, no specific biomarkers for the use of everolimus have been reported. Further studies are needed to identify and validate targets of therapy in endocrine-responsive breast cancer. ..
  3. doi Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study
    Kathleen I Pritchard
    Ontario Clinical Oncology Group, McMaster University, Hamilton, Canada
    J Clin Oncol 30:1274-9. 2012
    ..2-[(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) is potentially useful in assessing lymph nodes and detecting distant metastases in women with primary breast cancer...
  4. ncbi HER2 and responsiveness of breast cancer to adjuvant chemotherapy
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre and the University of Toronto, Toronto, ON, Canada
    N Engl J Med 354:2103-11. 2006
    ....
  5. ncbi Combining endocrine agents with chemotherapy: which patients and what sequence?
    Kathleen I Pritchard
    Clinical Trials and Epidemiology, University of Toronto at Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
    Cancer 112:718-22. 2008
    ..Considering the demonstrated importance of the timing of chemotherapy and tamoxifen in the postmenopausal setting, these questions should be explored further...
  6. doi Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and University of Toronto, 2075 Bayview Avenue, M4N 3M5, Toronto, ON, Canada
    Breast Cancer Res Treat 123:453-61. 2010
    ..While there appeared to be a trend toward improved efficacy with HD and LD versus AD, no significant differences could be shown. A parallel study (FINDER1) has reported similar findings in Japanese patients...
  7. doi HER-2 and topoisomerase II as predictors of response to chemotherapy
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre, Department of Medicine, University of Toronto, 2075 Bayview Ave, Toronto, ON, Canada
    J Clin Oncol 26:736-44. 2008
    ..Additional studies will be required to clarify these relationships...
  8. ncbi Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre, Toronto, Canada
    Oncology (Williston Park) 23:27-33. 2009
    ..Endocrine therapy with ovarian ablation, tamoxifen, or the combination is also useful in the metastatic setting in premenopausal women...
  9. ncbi Cardiovascular health and aromatase inhibitors
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre, Sunnybrook Health Sciences Centre, and the University of Toronto, Toronto, Ontario, Canada
    Drugs 66:1727-40. 2006
    ..Moreover, physicians should assess cardiovascular risk, and monitor and treat patients already diagnosed with or at risk for coronary heart disease, according to established guidelines...
  10. ncbi Risk of chemotherapy induced menopause: more detailed data will lead to improved quality of life
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre, Sunnybrook Health Sciences Centre and the University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Eur J Cancer 43:1644-5. 2007
  11. doi Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre, The University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
    Breast Cancer Res Treat 131:541-51. 2012
    ..5. An appropriately powered meta-analysis is required to discriminate the predictive value of these three candidate markers...
  12. doi Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:3869-76. 2011
    ..This trial was undertaken to assess whether octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence...
  13. ncbi Adjuvant therapy of the very young woman
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Canada M4N 3M5
    Breast 16:S136-46. 2007
    ..In the future more sophisticated molecular factors may identify those who require hormones alone, chemotherapy alone, newer biologic therapies, or combinations of these approaches...
  14. ncbi Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis
    Judith Anne W Chapman
    Department of Public Health Sciences, Faculty of Medicine, University of Toronto, and Department of Laboratory Medicine and Pathology, St Michael s Hospital, Toronto, Ontario, Canada
    Breast J 12:37-47. 2006
    ..Estimated prognoses may differ substantially by survival analysis model type, by amounts that might affect patient management, and we think that the log-normal model has a major advantage over the Cox model for survival analysis...
  15. ncbi Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes
    Pamela J Goodwin
    Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    Breast Cancer Res Treat 74:65-76. 2002
    ..The adverse effect of IGFBP-3 on distant recurrence in postmenopausal women with estrogen receptor positive breast cancer should be further investigated...
  16. ncbi Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system
    Harriette J Kahn
    Department of Pathology, Sunnybrook and Women s College Health Sciences Center, Toronto, Ontario, Canada
    Breast J 12:294-301. 2006
    ..This information is important with regard to the practice of sentinel node biopsy and subsequent axillary node dissection and to the decision to administer adjuvant therapy based on detection of micrometastases in lymph nodes...
  17. doi Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review
    Andrea Eisen
    Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5
    Cancer Treat Rev 34:157-74. 2008
    ....
  18. ncbi Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
    Edith A Perez
    St Michael s Hospital, Toronto, Canada
    J Clin Oncol 24:3629-35. 2006
    ..17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen...
  19. ncbi Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study
    Mala Bahl
    The Samuel Lunenfeld Research Institute and Department of Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 94:135-44. 2005
    ..Here, we examine whether serum levels of total cholesterol (TC) and triglycerides (TG) influence breast cancer outcome...
  20. ncbi A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  21. ncbi HER2/neu in systemic therapy for women with breast cancer: a systematic review
    Bindi Dhesy-Thind
    Juravinski Cancer Centre, Hamilton, ON, Canada
    Breast Cancer Res Treat 109:209-29. 2008
    ..Many studies have suggested that this gene may be associated with the relative efficacy of chemotherapy and endocrine therapy options...
  22. doi Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations
    Pamela J Goodwin
    Mount Sinai Hospital, 1284 600 University Ave, Toronto, Ontario M5G 1X5, Canada
    J Clin Oncol 30:164-71. 2012
    ....
  23. ncbi Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?
    Pamela J Goodwin
    Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Oncol 23:6037-42. 2005
    ..It has been suggested that leptin may mediate adverse prognostic effects of obesity in breast cancer...
  24. ncbi High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome
    Pamela J Goodwin
    Department of Medicine, Division of Clinical Epidemiology at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, 1284 600 University Avenue, Toronto, ON, Canada M5G 1X5
    Breast Cancer Res Treat 114:517-25. 2009
    ....
  25. doi Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer
    Pamela J Goodwin
    Mount Sinai Hospital, 1284 600 University Ave, Toronto, Ontario M5G 1X4, Canada
    J Clin Oncol 27:3757-63. 2009
    ..Such effects are biologically plausible given the presence of vitamin D receptors in breast cancer cells, which act as nuclear transcription factors to regulate gene activity...
  26. ncbi Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16
    Michael Crump
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 26:37-43. 2008
    ....
  27. doi Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growt
    Nan Soon Wong
    Sunnybrook Odette Cancer Centre, Ontario Clinical Oncology Group, University of Toronto, 2075 Bayview Ave, Toronto M4N3M5, Ontario, Canada
    J Clin Oncol 28:723-30. 2010
    ..There was no correlation between response and VEGF, sVEGFR-1, or sVEGFR-2 levels. CONCLUSION Metronomic dalCMP is safe, well tolerated, and clinically active in MBC...
  28. ncbi Diet and breast cancer: evidence that extremes in diet are associated with poor survival
    Pamela J Goodwin
    Department of Medicine, Sam Lunenfeld Research Institute Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Oncol 21:2500-7. 2003
    ..Because of a U-shaped association of body mass index (BMI) with survival in breast cancer, we hypothesized that a nonlinear association also existed for dietary variables...
  29. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  30. ncbi Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Tr
    Mark N Levine
    Department of Clinical Epidemiology, McMaster University, Hamilton, Ontario, Canada
    J Clin Oncol 23:5166-70. 2005
    ....
  31. pmc Review of the clinical studies using the 21-gene assay
    Catherine M Kelly
    Division of Medical Oncology, Sunnybrook Odette Cancer Centre, The University of Toronto, Toronto, Ontario, Canada, M4N 3M5
    Oncologist 15:447-56. 2010
    ..Better prognostic and predictive tests are needed. The 21-gene assay is the only widely commercially available gene signature that can be performed on formalin-fixed paraffin-embedded tissue...
  32. ncbi Managing patients on endocrine therapy: focus on quality-of-life issues
    Timothy J Whelan
    McMaster University, Hamilton, Ontario, Canada
    Clin Cancer Res 12:1056s-1060s. 2006
    ..To review the health-related quality of life (QOL) of women treated with adjuvant hormonal therapy...
  33. ncbi Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables
    Pamela J Goodwin
    Mount Sinai Hospital, 1284 600 University Avenue, Toronto, Ontario M5G 1X4, Canada
    J Clin Oncol 22:4184-92. 2004
    ..Evidence that psychosocial status and health-related quality of life (HRQOL) are associated with breast cancer (BC) outcomes is weak and inconsistent. We examined prognostic effects of these factors in a prospective cohort study...
  34. ncbi The best use of adjuvant endocrine treatments
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Breast 12:497-508. 2003
    ..Her-2 neu status is being explored as a predictive factor for selection of endocrine therapy, but is not yet considered standard for this purpose...
  35. pmc A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium
    Sara K Taylor
    5 105 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Oncologist 15:810-8. 2010
    ..We evaluated the activity of single-agent pazopanib in recurrent or metastatic breast cancer (MBC)...
  36. ncbi Adjuvant endocrine therapies for pre-/perimenopausal women
    Kathleen I Pritchard
    Clinical Trials and Epidemiology, Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ont, Canada M4N 3M5
    Breast 14:547-54. 2005
    ..The presence of these steroid hormone receptors remains the most useful predictive factor in selecting therapy for breast cancer...
  37. ncbi Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial
    Ian S Dayes
    Department of Oncology, McMaster University, Hamilton, Ontario, Canada
    Breast Cancer Res Treat 110:337-42. 2008
    ..In two centres, patients presenting to lymphedema clinic were screened for eligibility to understand the accrual process and help define the patient population...
  38. ncbi Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
    James R Wright
    Juravinski Cancer Center at Hamilton Health Sciences, Hamilton, Ontario, Canada
    J Clin Oncol 25:1027-32. 2007
    ..We designed a trial to investigate the effects of epoetin alfa therapy on the QOL of anemic patients with advanced non-small-cell carcinoma of the lung (NSCLC)...
  39. ncbi Prognostic factors affecting the natural history of node-negative breast cancer
    Maureen E Trudeau
    Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    Breast Cancer Res Treat 89:35-45. 2005
    ..We undertook a natural history investigation of a broad selection of prognostic factors in a cohort of women with node-negative breast cancer...
  40. ncbi Insulin-lowering effects of metformin in women with early breast cancer
    Pamela J Goodwin
    Department of Medicine, University of Toronto, Division of Clinical Epidemiology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Breast Cancer 8:501-5. 2008
    ..If metformin lowers insulin levels in women with breast cancer, it may also improve breast cancer outcomes...
  41. ncbi A review of exemestane in the management of breast cancer
    Nan Soon Wong
    Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario, Canada
    Expert Opin Pharmacother 6:2353-63. 2005
    ..In early breast cancer, key questions remain regarding the optimal sequence, duration and type of aromatase inhibitors, as well as their long-term safety...
  42. doi Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer
    Susan F Dent
    The Ottawa Hospital Cancer Centre, The University of Ottawa, 501 Smyth Rd, Ottawa, ON, K1H 8L6, Canada
    Breast Cancer Res Treat 126:295-310. 2011
    ..Prompt therapeutic management of common side effects associated with AIs may provide patients with the opportunity to receive the full benefit of their adjuvant hormonal treatment while minimizing toxicity...
  43. ncbi Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19
    Jianhua Liu
    National Cancer Institute of Canada Clinical Trials Group, Cancer Research Institute, Queens University, 10 Stuart Street, K7L3N6, Kingston, Ontario, Canada
    Breast Cancer Res Treat 100:263-71. 2006
    ..However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL)...
  44. ncbi The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer
    Shelley B Bull
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada
    J Clin Oncol 22:86-96. 2004
    ..On the basis of evidence that p53 mutation is involved in the development of human neoplasia, we examined the prognostic value of p53 alterations in combination with neu/erbB-2 amplification...
  45. doi Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene
    Tao Deng
    Toronto General Research Institute University Health Network, Ontario, Canada
    Clin Cancer Res 15:119-30. 2009
    ..Here we tested the hypothesis that DPPE targets breast tumor-initiating cells (TICs)...
  46. pmc Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
    Catherine M Kelly
    Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada
    BMJ 340:c693. 2010
    ..To characterise whether some selective serotonin reuptake inhibitor (SSRI) antidepressants reduce tamoxifen's effectiveness by inhibiting its bioactivation by cytochrome P450 2D6 (CYP2D6)...
  47. pmc Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer
    Daphne T Tsoi
    Division of Medical Oncology, Sunnybrook Odette Cancer Centre, The University of Toronto, Toronto, Ontario M4N 3M5, Canada
    Oncologist 15:457-65. 2010
    ..We evaluated the cost-effectiveness of recurrence score (RS)-guided treatment using 21-gene assay as compared with treatment guided by the Adjuvant! Online program (AOL)...
  48. ncbi Adjuvant therapy for early breast cancer: where do we stand today?
    Kathleen I Pritchard
    Department of Medicine, Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
    MedGenMed 5:17. 2003
  49. ncbi Endocrine therapy of advanced disease: analysis and implications of the existing data
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Ontario, M4N 3M5 Canada
    Clin Cancer Res 9:460S-7S. 2003
    ..The use of estrogen and progesterone receptor status to select for endocrine therapy is undeniably crucial. HER2/neu overexpression may also predict response to endocrine therapy, but this remains controversial...
  50. doi Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors
    Louise Bordeleau
    Department of Oncology, Juravinski Cancer Centre, 699 Concession St, Hamilton, Ontario, Canada L8V 5C2
    J Clin Oncol 28:5147-52. 2010
    ..Antidepressants and gabapentin have been shown to be both effective and well tolerated; however, it is not clear which is preferred...
  51. doi Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
    Pamela J Goodwin
    Department of Medicine, Division of Clinical Epidemiology at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
    Breast Cancer Res Treat 126:215-20. 2011
    ..32) that has recently been initiated...
  52. ncbi Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy
    Mark J Clemons
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 24:4895-900. 2006
    ....
  53. pmc Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial
    Maggie C U Cheang
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA
    Clin Cancer Res 18:2402-12. 2012
    ..CTG MA.5, a clinical trial randomizing premenopausal women with node-positive breast cancer to adjuvant CMF (cyclophosphamide-methotrexate-fluorouracil) versus CEF (cyclophosphamide-epirubicin-fluorouracil) chemotherapy...
  54. ncbi A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer
    Eileen Rakovitch
    Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
    Breast Cancer Res Treat 77:285-93. 2003
    ..To assess how women with ductal carcinoma in situ (DCIS) perceive their risks of recurrence, dying from breast cancer, and psychological distress compared to women with early stage invasive breast cancer (EIBC)...
  55. ncbi Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data
    Louise Bordeleau
    Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5
    J Clin Oncol 21:1944-51. 2003
    ..To evaluate the effect of a standardized group psychosocial intervention on health-related quality of life (HrQOL) in women with metastatic breast cancer and to explore the effect of missing data in HrQOL analyses...
  56. ncbi Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study
    Pamela J Goodwin
    Department of Medicine, Division of Clinical Epidemiology at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario M5G 1X5, Canada
    J Clin Oncol 20:42-51. 2002
    ..Because of this and because of its recognized association with obesity, an adverse prognostic factor in breast cancer, we examined the prognostic associations of insulin in early-stage breast cancer...
  57. doi Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer
    Eva Grunfeld
    Ontario Institute for Cancer Research, Ontario, Canada
    J Clin Oncol 29:4755-62. 2011
    ..An Institute of Medicine report recommends that patients with cancer receive a survivorship care plan (SCP). The trial objective was to determine if an SCP for breast cancer survivors improves patient-reported outcomes...
  58. pmc Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines
    Lawson Eng
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada
    BMC Med Genomics 4:18. 2011
    ..Ingenuity Pathway Analysis software helped us understand how our identified genes may alter the cellular response to paclitaxel...
  59. ncbi Estimating per patient funding for cancer clinical trials: an Ontario based survey
    James R Wright
    Juravinski Cancer Center, Hamilton Health Sciences, 699 Concession St, Hamilton, Ontario, Canada, L8V 5C2
    Contemp Clin Trials 26:421-9. 2005
    ..These issues are likely not unique to oncology...
  60. ncbi Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
    Mark J Clemons
    Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa Hospital Research Institute and University of Ottawa, Box 912, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada
    Breast Cancer Res Treat 146:153-62. 2014
    ..04-2.30) and for OS, HR = 2.32 (95 % CI 1.25-4.33). The addition of vandetanib to fulvestrant did not improve biomarker response, PFS or OS in patients with bone metastases. Baseline bone turnover was prognostic for PFS and OS. ..
  61. doi The impact of a breast cancer diagnosis in young women on their relationship with their mothers
    Asma Ali
    Department of Medicine, Division of Medical Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada Electronic address
    Breast 23:50-5. 2014
    ..For young women with breast cancer mothers might either be a source of support or of increased stress, depending on the premorbid relationship and on the psychological effect of the daughter's diagnosis on her mother...
  62. ncbi Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference
    Steven E Come
    Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 112:673-8. 2008
    ..All of this has and continues to contribute to a growing understanding of how to optimize the use of endocrine agents in both treating and preventing breast cancer...
  63. ncbi Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials
    Federica Cuppone
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Cancer 112:260-7. 2008
    ..0] was demonstrated...
  64. ncbi Adjuvant therapy for breast cancer: we are solving the puzzle, but pieces are still missing
    Kathleen I Pritchard
    J Natl Cancer Inst 99:494-5. 2007
  65. ncbi neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II
    Kathleen I Pritchard
    J Clin Oncol 21:399-400. 2003
  66. ncbi Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain
    Nan Soon Wong
    J Clin Oncol 25:3787. 2007
  67. ncbi Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007
    ..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status...
  68. ncbi Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 9:443S-6S. 2003
  69. ncbi Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2127-32. 2007
    ....
  70. ncbi Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?
    Kathleen I Pritchard
    J Clin Oncol 20:4611-4. 2002
  71. ncbi American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002
    Eric P Winer
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3317-27. 2002
    ..POTENTIAL INTERVENTIONS: Anastrozole, letrozole, and exemestane...
  72. ncbi Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  73. ncbi Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement
    Steven E Come
    Breast Cancer Program, Beth Israel Deaconess Medical Center Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 12:997s-1000s. 2006
  74. ncbi Optimal chemotherapy for women with breast cancer: the plot thickens
    Joseph L Pater
    J Clin Oncol 21:963-4. 2003
  75. ncbi Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5
    Wendy R Parulekar
    National Cancer Institute of Canada Clinical Trials Group, Queens University, 10 Stuart St, Kingston, Ontario K7L3N6, Canada
    J Clin Oncol 23:6002-8. 2005
    ..To investigate the therapeutic impact of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer...
  76. doi Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review
    Yolanda Madarnas
    Cancer Centre of Southeastern Ontario, Kingston General Hospital, 25 King Street West, Kingston, ON, Canada K7L 5P9
    Cancer Treat Rev 34:539-57. 2008
    ....
  77. ncbi Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    Paul E Goss
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 97:1262-71. 2005
    ..This report presents updated findings from the trial...
  78. ncbi Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen
    Kathleen I Pritchard
    J Clin Oncol 23:4850-2. 2005
  79. doi Antihormone therapy in recurrent metastatic breast cancer
    Kathleen I Pritchard
    JAMA 299:2745; author reply 2745. 2008
  80. ncbi American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 23:619-29. 2005
    ..To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors...
  81. doi Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
    J Clin Oncol 26:1948-55. 2008
    ..When the trial was unblinded, patients who received placebo (PLAC) were offered LET...
  82. doi Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17
    Hyman B Muss
    University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA
    J Clin Oncol 26:1956-64. 2008
    ..Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA.17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on older women...
  83. ncbi Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care
    Eva Grunfeld
    Cancer Outcomes Research Program, Cancer Care Nova Scotia and Dalhousie University, Halifax, Nova Scotia
    J Clin Oncol 24:848-55. 2006
    ..It is usual practice for routine follow-up to take place in specialist clinics. This study tested the hypothesis that follow-up by the patient's family physician is a safe and acceptable alternative to specialist follow-up...
  84. ncbi American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting
    Eric P Winer
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 21:2597-9. 2003
  85. doi Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials
    Julie Lemieux
    Unité de recherche en santé des populations, Centre des Maladies du Sein Deschênes Fabia, Hôpital St Sacrement, Quebec, Canada
    J Clin Oncol 26:4458-65. 2008
    ..Barriers to participation may relate to available protocols, physicians, and patients, but few data exist on barriers related to cancer care environments and protocol characteristics...
  86. pmc Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer and Department of Medicine, University of Toronto, Ont
    CMAJ 166:1017-22. 2002
    ..To provide information and recommendations to women with a previous diagnosis of breast cancer and their physicians regarding hormone replacement therapy (HRT)...
  87. ncbi Should observational studies be a thing of the past?
    Kathleen I Pritchard
    J Natl Cancer Inst 100:451-2. 2008